為保障新型冠狀病毒肺炎（COVID-19）突發(fā)公共衛(wèi)生事件中藥品供應(yīng)穩(wěn)定，2020年4月歐盟發(fā)布了“COVID-19持續(xù)期間的最優(yōu)和合理藥品供應(yīng)以避免藥品短缺的指導(dǎo)原則”。該指導(dǎo)原則提供了公共衛(wèi)生事件期間，歐盟成員國(guó)維持藥品供應(yīng)穩(wěn)定應(yīng)遵循的工作建議；并針對(duì)COVID-19治療用藥品和因疫情影響而具有短缺風(fēng)險(xiǎn)的藥品，提出維持藥品供應(yīng)、流通和使用的最優(yōu)措施。介紹該指導(dǎo)原則的主要內(nèi)容，以期為完善中國(guó)公共衛(wèi)生體系建設(shè)提供參考。

To ensure the stable supply of medicines in European Union (EU) during the coronavirus disease 2019 (COVID-19) public health emergency, EU has published Guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak in April 2020. This guideline aimed to prompt EU Member States with concrete actions for the stable supply of medicines during the public health emergency. The guideline focused on the rational supply, allocation and use of medicines to treat COVID-19 patients but also covered any medicine at risk of shortage due to the pandemic. The main content of this guideline is introduced, which is expected to provide reference for perfecting the public health system of China.

R951